Question 1

What is pharma competitive intelligence?

Accepted Answer

Pharma competitive intelligence is the work of tracking what other drug, biologic, and device companies are doing: the trials they run, the approvals and label changes they receive, the patents and exclusivities that protect their products, the FDA actions taken against them, and what they disclose to investors. Good competitive intelligence pulls these signals from primary sources into one view that BD, regulatory, and leadership teams can act on.

Question 2

Which sources does Assyro search for competitive intelligence?

Accepted Answer

Assyro searches ClinicalTrials.gov, the EU trial registers (CTIS and the EU Clinical Trials Register), FDA databases including Drugs@FDA, complete response letters, enforcement reports and recalls, FAERS, 510(k), PMA, and MAUDE, the FDA Orange Book and Purple Book, the FDA Data Dashboard, SEC EDGAR filings, EMA, MHRA, the Health Canada drug and device databases, the Federal Register, Regulations.gov, PubMed, Europe PMC, DailyMed, and RxNorm.

Question 3

How do I track a competitor's drug pipeline?

Accepted Answer

Drug pipeline tracking starts with trial registries. Assyro searches ClinicalTrials.gov by sponsor, condition, or drug and the EU trial registers by drug and country, then adds published results from PubMed and Europe PMC and the trial readouts companies disclose in SEC filings. Ask a question such as which phase 3 trials a competitor is running in an indication, and each trial in the answer is cited by its registry number.

Question 4

Can Assyro show competitor PDUFA dates?

Accepted Answer

FDA does not publish PDUFA target action dates for most applications. Companies often disclose them to investors. Assyro searches SEC EDGAR filings (8-K, 10-K, 10-Q, 20-F, and more), so you can find the PDUFA dates a competitor has disclosed, with the filing cited. A date a company never disclosed will not appear. For a calendar view, the free FDA PDUFA calendar on assyro.com lists dates from FDA pages, FDA datasets, and sponsor disclosures.

Question 5

How is this different from asking a general AI chatbot?

Accepted Answer

A general chatbot answers from what it absorbed in training and often cannot show where a claim came from. Assyro searches the named primary sources when you ask and links each statement to the record behind it, such as an NCT number, an FDA approval or recall record, or an SEC filing. Your team can open the record and check it before the answer goes into a memo or a deal model.

Question 6

Can I get alerts when a competitor's record changes?

Accepted Answer

Yes. Save a search on a competitor, drug, or indication as a watch. Assyro checks it on the schedule you choose and emails you the records it has not shown you before, each linked to its source. Assyro brings you the new record. Your team decides what it means for your strategy.

Question 7

Does Assyro cover generic and biosimilar competition?

Accepted Answer

Yes. The FDA Orange Book covers approved drug products, therapeutic equivalence codes, reference listed drugs, patents, and exclusivities, which shape when generics can enter. The FDA Purple Book covers licensed biologics, biosimilars, interchangeability, and reference product exclusivity. Answers state the monthly edition they come from.

Question 8

Does competitive intelligence cover medical devices?

Accepted Answer

Yes. For MedTech competitors, Assyro searches FDA 510(k) clearances, PMA approvals, product classification, MAUDE adverse event reports, device recalls, and Health Canada medical device licences. Cross-source profiles show one device type by FDA product code across every linked source.

Question 9

Is competitive intelligence the same as regulatory intelligence?

Accepted Answer

No. Regulatory intelligence tracks what regulators require, such as new guidance, rules, and policy changes. Competitive intelligence tracks what other companies are doing, such as their trials, approvals, patents, and FDA actions. Assyro covers both from the same cited sources, so a regulatory lead and a BD lead can work from one set of records.

Track Competitor Trials, Approvals, and FDA Actions in One Place

Pharma Competitive Intelligence From Primary Sources

See Competitor Trials Across US and EU Registries

Track Approvals, Patents, and Exclusivity Before Generics Arrive

Read Competitor CRLs, Recalls, and Inspection Findings

Get an Email When a Competitor's Record Changes

Competitive Intelligence Your Team Can Verify

Every Claim Links to Its Source Record

Profile a Drug or Device Type Across Linked Sources

Guides for your next decision

Questions About Pharma Competitive Intelligence

See Competitive Intelligence on Your Own Competitors.